Two BRM promoter polymorphisms predict poor survival in patients with hepatocellular carcinoma.
Pasic I, Wong KM, Lee JJ, Espin-Garcia O, Brhane Y, Cheng D, Chen Z, Patel D, Brown C, Bucur R, Reisman D, Knox JJ, Xu W, Hung RJ, Liu G, Cleary SP.
Pasic I, et al.
Mol Carcinog. 2018 Jan;57(1):106-113. doi: 10.1002/mc.22736. Epub 2017 Oct 9.
Mol Carcinog. 2018.
PMID: 28892201